WAVEMAN · COMPANY

INDV · Indivior Pharmaceuticals, Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

INDV

Name: Indivior Pharmaceuticals, Inc. (INDV) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Indivior Pharmaceuticals, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001625297

C-SUITE BUYING · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$2.7M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

208

13F, latest reported quarter

REVENUE GROWTH

+4.3%

XBRL, annual

NET MARGIN

16.9%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$2.7M over 180 days

-$2.7M over 90 days

below 72% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

208 funds added or opened last quarter

more than 88% of Pharma & Biotech

REVENUE

+4.3% year over year

more than 53% of Pharma & Biotech

MARGIN

16.9% net margin

more than 87% of Pharma & Biotech

BUYBACKS

$302.0M repurchased, FY to 2026-06-30

more than 83% of Pharma & Biotech

SHORT

9.2% of shares outstanding short · 7.1 days to cover · settled 2026-07-31

more than 73% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

208 funds added or opened positions in the latest 13F quarter, of 341 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +41.6%

+41.6%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $2.7M sold by insiders over 180 days, 208 funds added last quarter, $764.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Indivior Pharmaceuticals, Inc. insiders sold a net $2.7M of stock across 13 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Anderson Woodrow D

Chief Accounting Officer

BUY

2026-08-27

1,500.0

$53.5K

Anderson Woodrow D

Chief Accounting Officer

BUY

2026-08-05

1,500.0

$54.4K

Heidbreder Christian

Chief Scientific Officer

SELL

2026-07-10

18,586.0

$764.6K

Heidbreder Christian

Chief Scientific Officer

SELL

2026-06-11

18,586.0

$707.4K

Preblick Ryan

Chief Financial Officer

SELL

2026-06-08

36,000.0

$1.4M

13 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 8 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

18,709,432.0 sh

$767.6M

VANGUARD PORTFOLIO MANAGEMENT LLC

7,572,287.0 sh

$310.7M

OAKTREE CAPITAL MANAGEMENT LP

6,127,212.0 sh

$251.4M

VANGUARD CAPITAL MANAGEMENT LLC

5,495,486.0 sh

$225.5M

STATE STREET CORP

4,992,071.0 sh

$204.8M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Heidbreder Christian

FILED 2026-07-10

$764.6K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

CapForce IBD 50 ETF

$2.8M POSITION · AS OF 2026-04-30

3.2%

Invesco S&P SmallCap Health Care ETF

$3.4M POSITION · AS OF 2026-02-28

2.4%

State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF

$5.5M POSITION · AS OF 2026-03-31

1.8%

Invesco S&P SmallCap Momentum ETF

$48.8M POSITION · AS OF 2026-04-30

1.8%

PROFUND VP PHARMACEUTICALS

$173.9K POSITION · AS OF 2026-03-31

1.7%

FULLERTHALER BEHAVIORAL SMALL-CAP GROWTH

$63.4M POSITION · AS OF 2026-03-31

1.5%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$1.2B	$1.2B	$1.1B	$901.0M
GROSS PROFIT	$994.0M	$957.0M	$919.0M	$749.0M
OPERATING INCOME	$262.0M	$38.0M	$-152.0M	$-77.0M
NET INCOME	$210.0M	$7.0M	$-126.0M	$-42.0M
EPS (DILUTED)	1.64	0.05	-0.92	-0.30
OPERATING CASH FLOW	$-27.0M	$36.0M	$-300.0M	$-4.0M
CASH	$195.0M	$319.0M	$316.0M	—
LONG-TERM DEBT	$290.0M	$315.0M	$237.0M	—
BUYBACKS	$11.0M	$173.0M	$33.0M	$90.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE